Leading Ebola Vaccine Candidates
DOI:
https://doi.org/10.17140/VROJ-1-101Abstract
The ongoing outbreak of Ebola Virus Disease (EVD) in West Africa is the largest outbreak ever recorded with a total number of 28,602 confirmed, probable, or suspected cases in Guinea, Liberia, and Sierra Leone, including 11,301 reported deaths since December 2013 (as of January 17, 2016).1 A meeting convened by the World Health Organization (WHO) in September, 2014, concluded that an urgent unmet need exists for efficacy and safety testing of the EVD vaccine candidates and that clinical trials should be expedited. These vaccines could be used both in an outbreak setting and to provide long-term protection in populations at risk of
sporadic outbreaks.
A number of vaccines have been evaluated in phase 1 trials including DNA vaccines, virus-like particles and viral vectors,2 but the two most advanced first-generation Ebola vaccines candidates are the live replicating Vesicular Stomatitis Virus (rVSV) and the replicationdefective chimpanzee adenovirus 3 (ChAd3).
References
2014 Ebola outbreak in West Africa - case counts. Centers for Disease Control and Prevention. Web site. http://www.cdc.gov/ vhf/ebola/outbreaks/2014-west-africa/case-counts.html. Updat-ed February 10, 2016. Accessed February 15, 2016.
Sridhar S. Clinical development of Ebola vaccines. Therapeutic Advances in Vaccines. 2015; 3:125-138. doi: 10.1177/2051013615611017
Jones SM, Feldmann H, Stroher U, et al. Live attenuated re-combinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nature Medicine. 2005; 11: 786-790. doi: 10.1038/nm1258
Agnandji ST, Huttner A, Zinser ME, et al. Phase 1 trials of rVSV Ebola vaccine in Africa and Europe - preliminary report. The New England Journal of Medicine. 2015. doi: 10.1056/NEJ-Moa1502924
Regules JA, Beigel JH, Paolino KM, et al. A recombinant ve-sicular stomatitis virus ebola vaccine - preliminary report. The New England Journal of Medicine. 2015. doi: 10.1056/NEJ-Moa1414216
Huttner A, Dayer JA, Yerly S, et al. The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vac-cine: a randomised double-blind, placebo-controlled phase 1/2 trial. The Lancet Infectious Diseases. 2015; 15: 1156-1166. doi: 10.1016/S1473-3099(15)00154-1
Henao-Restrepo AM, Longini IM, Egger M, et al. Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vac-cination cluster-randomised trial. Lancet. 2015; 386: 857-866. doi: 10.1016/S0140-6736(15)61117-5
Geisbert TW, Feldmann H. Recombinant vesicular stomatitis virus-based vaccines against Ebola and Marburg virus infec-tions. The Journal of Infectious Diseases. 2011; 204 Suppl 3: S1075-S1081. doi: 10.1371/journal.pntd.0001567
Gulland A. Ebola vaccine will be made available for emer-gency use. BMJ. 2016; 352: i386. doi: 10.1136/bmj.i386
Ledgerwood JE, DeZure AD, Stanley DA, et al. Chimpan-zee Adenovirus Vector Ebola Vaccine - Preliminary Report. The New England Journal of Medicine. 2014. doi: 10.1056/NEJ-Moa1410863
Stanley DA, Honko AN, Asiedu C, et al. Chimpanzee adeno-virus vaccine generates acute and durable protective immunity against ebolavirus challenge. Nature Medicine. 2014; 20: 1126- 1129. doi:10.1038/nm.3702
Sullivan NJ, Martin JE, Graham BS, Nabel GJ. Correlates of protective immunity for Ebola vaccines: implications for regula-tory approval by the animal rule. Nature Reviews Microbiology. 2009; 7: 393-400. doi:10.1038/nrmicro2129
Rampling T, Ewer K, Bowyer G, et al. A Monovalent Chim-panzee Adenovirus Ebola Vaccine - Preliminary Report. The New England Journal of Medicine. 2015. doi: 10.1056/NEJ-Moa1411627
De Santis O, Audran R, Pothin E, et al. Safety and immuno-genicity of a chimpanzee adenovirus-vectored Ebola vaccine in healthy adults: a randomised, double-blind, placebo-controlled, dose-finding, phase 1/2a study. The Lancet Infectious Diseases. 2015. doi: 10.1016/S1473-3099(15)00486-7
Tapia MD, Sow SO, Lyke KE, et al. Use of ChAd3-EBO-Z Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA-BN-Filo: a phase 1, single-blind, randomised trial, a phase 1b, open-label and double-blind, dose-escalation trial, and a nested, randomised, double-blind, place-bo-controlled trial. The Lancet Infectious Diseases. 2016; 16: 31-42. doi: 10.1016/S1473-3099(15)00362-X
Johnson & Johnson Announces Major Commitment to Speed Ebola Vaccine Development and Significantly Expand Production. Johnson & Johnson. Web site. http://www.jnj.com/ news/all/Johnson-Johnson-Announces-Major-Commitment-to-Speed-Ebola-Vaccine-Development-and-Significantly-Expand-Production. Accessed January 25, 2016.
Staged phase 3 Study to Assess the Safety and Immunoge-nicity of Ebola Candidate Vaccines Ad26.ZEBOV and MVA-BN-Filo During Implementation of Stages 1 and 2 (EBOVAC-Salone). ClinicalTrails.gov. Web site. https://clinicaltrials.gov/ ct2/show/NCT02509494. Accessed January 25, 2016.
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content published in Vaccination Research (VR) is licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows anyone to copy, distribute, transmit, and adapt the work — including for commercial purposes — provided appropriate credit is given to the original author(s) and source.